Search

Displaying results 1661 - 1670 of 7540 in total
  1. Drug

    Lepirudin

    go.drugbank.com/drugs/DB00001
    ApprovedWithdrawn

    [A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4. … at position 1 (N-terminal end).

  2. Drug

    Cyanocobalamin Co-60

    go.drugbank.com/drugs/DB09387
    ApprovedWithdrawn

    Cyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons. … Cyanocobalamin Co-60 is an analog of Vitamin B12 labeled with Co60.

    Synonyms: Cyanocobalamin Co 60, Cyanocobalamin Co-60
  3. Drug

    Bentoquatam

    go.drugbank.com/drugs/DB00516
    Approved

    Bentoquatam is a topical medication intended to act as a shield against exposure to the irritating substance urushiol, found in plants such as poison ivy or poison oak. … Bentoquatam contains bentonite, a clay, and is only effective as long as the film is visible on the skin.

  4. Drug

    Velpatasvir

    go.drugbank.com/drugs/DB11613
    ApprovedInvestigational

    Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … Velpatasvir acts as a defective substrate for NS5A (Non-Structural Protein 5A), a non-enzymatic viral protein that plays a key role in Hepatitis C Virus replication, assembly, and modulation of host immune

  5. Drug

    Lumiracoxib

    go.drugbank.com/drugs/DB01283
    ApprovedWithdrawn

    Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). … On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver

    Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal
  6. Drug

    Nebivolol

    go.drugbank.com/drugs/DB04861
    ApprovedInvestigational

    [A182594] Nebivolol was granted FDA approval on 17 December 2007.[L7985] … [A182579] Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics.

    Products: CORETEL-N
  7. Drug

    Tolvaptan

    go.drugbank.com/drugs/DB06212
    ApprovedInvestigational

    FDA approved on May 19, 2009. … Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH

  8. Drug

    Tirbanibulin

    go.drugbank.com/drugs/DB06137
    ApprovedInvestigational

    [A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. … [L27806] Actinic keratosis is a chronic condition characterized by lesions, which can potentially transform into invasive squamous cell carcinoma with a risk of 1% over 10 years.

  9. Drug

    Talazoparib

    go.drugbank.com/drugs/DB11760
    ApprovedInvestigational

    [L47236] Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 [A260346] and by the EMA in June 2019.[L47296] It was approved by Health Canada in September 2020.

  10. Drug

    Bethanechol

    go.drugbank.com/drugs/DB01019
    Approved

    An advantage of bethanechol is that in contrast to acetylcholine, bethanechol is not degraded by cholinesterase allowing its effects to be longer-lasting.[L32539] … [A232905,L32539] For example, bethanechol is readily used to treat postoperative or postpartum urinary retention.

    Synonyms: 2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminium